Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
solrikitug
- Development stage
- Phase 2
- Lead developer
- Uniquity Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Solrikitug is a humanized IgG1-kappa monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), an upstream cytokine involved in type 2 inflammation. By binding to TSLP and inhibiting its interaction with the TSLP receptor complex (TSLPR and IL-7Rα), solrikitug blocks downstream signaling pathways that drive eosinophilic inflammation. This mechanism is relevant for diseases such as asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). Solrikitug has demonstrated unique epitope binding compared to tezepelumab and superior potency in preclinical assays. It is currently being developed by Uniquity Bio for immune-mediated respiratory and gastrointestinal diseases[1][2][4][5].
- Other names
- solrikitugImmunoglobulin G1-kappa, anti-[Homo sapiens CRLF2 (cytokine receptor like factor 2, TSLP, thymic stromal lymphopoietin)], humanized monoclonal antibody
02
Targets
TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on solrikitug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on solrikitug.